2020 July 27

iCure B&P Co., Ltd. and the Institute of Biotechnology signed a joint development agreement for a "peptide anti-cancer drug" on July 27, 2020.

SYP Co., Ltd. discovered the demand for iCure B&P Co., Ltd., matched with life (research) holding technology, carried out BM planning, and plays an additional BM development and investment linkage role.

The full article is as follows.

Person in charge: Patent Attorney Kim Bo-yeol (kby@sypip.com ) 

iCure announced on the 27th that its subsidiary iCure BNP has signed an agreement with the Korea Biotechnology Research Institute to jointly develop new drugs for peptide anticancer drugs.

The joint study aims to develop an oral peptide innovative anticancer drug that increases anticancer efficacy, reduces side effects, and improves ease of use by combining iCureBNP's bio-better oral drug delivery with a newly developed cancer treatment target VGLL1.

In addition, allowing the developed oral anticancer drug to enter the global market is the main background of the joint development of new peptide anticancer drugs. 

According to iCure, peptide anticancer drugs have only been developed as injections due to their low metabolic stability, and peptide hormone lupron is a representative peptide anticancer drug marketed as a treatment for prostate cancer. With the recent development of peptide-related technologies, the development of peptides and peptide-derived anticancer drugs with high clinical success rates due to high physiological activity, easy mass production, and low toxicity is drawing attention.

A company official said, "This joint study is significant in that it develops the world's first oral innovative peptide anticancer drug that overcomes the shortcomings of the low metabolic stability of peptides."

"We are preparing a commercialization strategy and roadmap through a joint research agreement," he said. "We will also consider promoting technology transfer contracts through technology development, rights, and commercialization."

This joint development agreement is aimed at carrying out the knowledge cluster PLUS task of the "2020 BIG Leading Model Project Based on Public Research Performance" (Ministry of Science and ICT), which was selected in June. It is the result of a bio-industry cluster in Chungcheong Province created by Korea Science and Technology Holding Company, an investment institution, SYP Co,Ltd., a technology commercialization institution, and Magna Investment as a bio-investment company.

The company said, "In order to create large-scale results in the future, we will proceed with the process of establishing a company in the form of a 'joint research corporation' through convergence BM and industrialization strategies."